| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/28/2002 | US20020037544 Detecting modulators of phosphorylation; obtain sample, incubate with modulator, screen sample for adjustment in phosphorylation activity |
| 03/28/2002 | US20020037543 Purging of cells using viruses |
| 03/28/2002 | US20020037540 Nucleotide sequences coding preferential tumor markers; for use tools in tumor detection and treatment |
| 03/28/2002 | US20020037524 Nucleotide sequences for use in diagnosis, treatment and prevention of cancer, inflammation, autoimmune disease and infections |
| 03/28/2002 | US20020037523 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of nervous system, autoimmune, inflammation, glomerulonephritis and osteoporosis disorders |
| 03/28/2002 | US20020037518 Polypeptide for use in the diagnosis, prevention and treatment of cell proliferation and inflammation defects |
| 03/28/2002 | US20020037296 For therapy and diagnosis of the human or animal body, anti-tumour prodrugs and those which are specifically activated by the hydroxylation activity of the P- 450 enzyme CYP1B1 |
| 03/28/2002 | US20020037289 Combined methods and compositions for tumor vasculature targeting and tumor treatment |
| 03/28/2002 | US20020037288 As therapeutic agents for T cell tumors or B cell tumors (excluding myeloma) |
| 03/28/2002 | US20020037287 For diagnosis and therapy of myeloma and ovarian cancer |
| 03/28/2002 | US20020037282 Universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
| 03/28/2002 | US20020037274 Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| 03/28/2002 | US20020037250 Polynucleotides and polypeptides which are diagnostic markers for mammary gland cancer. |
| 03/28/2002 | DE10135996A1 Identifying metastatic tumor cells and screening for antitumor agents, comprises hybridization to specific cDNA sequences |
| 03/28/2002 | DE10046318A1 Detecting tumor cells from presence of specific stem-loop DNA molecules outside the nucleus, useful for diagnosis and monitoring of tumors |
| 03/28/2002 | DE10045592A1 Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie An antibody-TNF TNF inhibitor fusion protein (TNF-Selektokin) as target-specific Prozytokin for tumor therapy |
| 03/28/2002 | DE10043437A1 Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites Using trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites |
| 03/28/2002 | CA2433157A1 Cyclopentane derivatives as therapeutic agents |
| 03/28/2002 | CA2424394A1 Growth factor complex comprising an insulin-like growth factor binding protein bound to vitronectin |
| 03/28/2002 | CA2423181A1 Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof |
| 03/28/2002 | CA2423154A1 Imidazole derivatives as raf kinase inhibitors |
| 03/28/2002 | CA2423106A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | CA2423071A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | CA2423058A1 Polypeptide having phospholipase a2 activity |
| 03/28/2002 | CA2423050A1 Pyrazine derivatives as modulators of tyrosine kinases |
| 03/28/2002 | CA2423039A1 Cancer associated protein kinases and their uses |
| 03/28/2002 | CA2422964A1 Method for reducing toxicity of combined chemotherapies |
| 03/28/2002 | CA2422923A1 Pyridine derivatives with ikb-kinase (ikk-.beta.) inhibiting activity |
| 03/28/2002 | CA2422625A1 Method for use of igf-binding protein for selective sensitization of target cells in vivo |
| 03/28/2002 | CA2422568A1 Prognostic indicator |
| 03/28/2002 | CA2422544A1 Conditionally replicating viral vectors and their use |
| 03/28/2002 | CA2422535A1 Treatment of diseases with adamantane derivatives |
| 03/28/2002 | CA2422215A1 B7-like molecules and uses thereof |
| 03/28/2002 | CA2421877A1 Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| 03/28/2002 | CA2421576A1 Human polynucleotides and polypeptides encoded thereby |
| 03/28/2002 | CA2421485A1 Water soluble rapamycin esters |
| 03/28/2002 | CA2421056A1 A polypeptide for use as a diagnostic marker for the presence of colon tumours |
| 03/28/2002 | CA2420862A1 Protein phosphatases |
| 03/28/2002 | CA2420210A1 Stereoselective process for preparing cyclohexyl amine derivatives |
| 03/27/2002 | EP1191036A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 03/27/2002 | EP1191025A1 Crystals of benzimidazole compounds |
| 03/27/2002 | EP1190726A2 Liquefied embolic materials capable of sol-gel phase transition and their use |
| 03/27/2002 | EP1190714A2 Method for the treatment of thromboembolic disorders in patients with aspirin resistance |
| 03/27/2002 | EP1190711A1 Treatment of diseases with adamantane derivatives |
| 03/27/2002 | EP1190099A1 Antisense modulation of pi3k p85 expression |
| 03/27/2002 | EP1190085A2 Non-squamous epithelium-specific transcription |
| 03/27/2002 | EP1190083A2 Dna constructs based on the eif4a gene promoter |
| 03/27/2002 | EP1190082A1 Method of inducing angiogenesis by micro-organs |
| 03/27/2002 | EP1190077A2 Genetic sequence which codes for the flavon synthase ii enzyme and use of the same |
| 03/27/2002 | EP1190074A1 Recombinant anti-cd40 antibody and uses thereof |
| 03/27/2002 | EP1190073A2 Control of gene expression |
| 03/27/2002 | EP1190072A2 22012, a novel human carboxypeptidase |
| 03/27/2002 | EP1190071A2 17867, a novel human aminopeptidase |
| 03/27/2002 | EP1190061A1 Streptavidin expressed gene fusions and methods of use thereof |
| 03/27/2002 | EP1190059A1 Sgip peptides |
| 03/27/2002 | EP1190057A1 Cloning and expression of a novel 5-ht4 receptor |
| 03/27/2002 | EP1190055A2 Human endogenous retrovirus in breast cancer |
| 03/27/2002 | EP1190054A1 Epithelial cell growth inhibitors |
| 03/27/2002 | EP1190052A1 16405 receptor, a g-protein coupled receptor |
| 03/27/2002 | EP1190051A2 Human transport proteins |
| 03/27/2002 | EP1190050A2 Human transcriptional regulator proteins |
| 03/27/2002 | EP1190049A1 Spliceosome protein and its use |
| 03/27/2002 | EP1190047A1 Antisense oligonucleotide modulating cyclin e gene expression and therapeutic uses thereof |
| 03/27/2002 | EP1190040A1 Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
| 03/27/2002 | EP1190038A2 Bacterial protection against stress |
| 03/27/2002 | EP1189947A1 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines |
| 03/27/2002 | EP1189946A1 ANTI-$g(a) v?$g(b)3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE |
| 03/27/2002 | EP1189942A1 Somatostatin agonists |
| 03/27/2002 | EP1189941A1 Neuromedin b and somatostatin receptor agonists |
| 03/27/2002 | EP1189939A1 Bh3 modified peptides |
| 03/27/2002 | EP1189936A2 Use of eif4e binding agents in therapy |
| 03/27/2002 | EP1189931A2 Peptide compounds that bind her2 |
| 03/27/2002 | EP1189930A1 INHIBITORS OF THE INTEGRIN AlPHA V BETA 6 |
| 03/27/2002 | EP1189922A1 Steroid derivatives |
| 03/27/2002 | EP1189917A1 48 human secreted proteins |
| 03/27/2002 | EP1189908A1 Indolocarbazole alkaloids from a marine actinomycete |
| 03/27/2002 | EP1189897A1 Isoflavone metabolites |
| 03/27/2002 | EP1189894A1 Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer |
| 03/27/2002 | EP1189892A1 Melamine derivatives as potent anti-cancer agents |
| 03/27/2002 | EP1189888A1 HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS $i(PDE 4) INHIBITORS |
| 03/27/2002 | EP1189887A2 Process for preparing 10,11-methanobenzosuberane derivatives |
| 03/27/2002 | EP1189883A2 Substituted pyrrolidines as cell adhesion inhibitors |
| 03/27/2002 | EP1189882A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor |
| 03/27/2002 | EP1189645A2 Non-covalent bioconjugates useful for diagnosis and therapy |
| 03/27/2002 | EP1189641A2 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/27/2002 | EP1189637A2 Compositions for improving bioavailability of orally administered drugs |
| 03/27/2002 | EP1189635A1 Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells |
| 03/27/2002 | EP1189634A1 Treating prostate cancer with anti-erbb2 antibodies |
| 03/27/2002 | EP1189628A1 Combination of tumor necrosis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 03/27/2002 | EP1189626A1 Method for preventing tumoral growth |
| 03/27/2002 | EP1189624A1 Hla binding peptides and their uses |
| 03/27/2002 | EP1189618A1 Thrombin inhibitors |
| 03/27/2002 | EP1189612A1 Vla-4 inhibitor compounds |
| 03/27/2002 | EP1189611A1 Cancer therapy |
| 03/27/2002 | EP1189609A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| 03/27/2002 | EP1189607A2 Anti-tumor activity of vitamin e, cholesterol, taxol and betulinic acid derivatives |
| 03/27/2002 | EP1189603A2 Treatment of immune diseases like hiv disease and neoplastic disorders |
| 03/27/2002 | EP1189583A1 Indole derivatives |
| 03/27/2002 | EP1077068B1 Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
| 03/27/2002 | EP1064284B1 Hypnotic beta-carboline derivatives, process for their preparation and their use as medicinal products |